Emyria Ltd
ASX:EMD
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Birla Corporation Ltd
NSE:BIRLACORPN
|
IN |
|
T
|
TA Corporation Ltd
SGX:PA3
|
SG |
Emyria Ltd
Total Liabilities
Emyria Ltd
Total Liabilities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Emyria Ltd
ASX:EMD
|
Total Liabilities
AU$1.3m
|
CAGR 3-Years
-12%
|
CAGR 5-Years
0%
|
CAGR 10-Years
N/A
|
|
|
Recce Pharmaceuticals Ltd
ASX:RCE
|
Total Liabilities
AU$20.7m
|
CAGR 3-Years
145%
|
CAGR 5-Years
71%
|
CAGR 10-Years
N/A
|
|
|
Mayne Pharma Group Ltd
ASX:MYX
|
Total Liabilities
AU$644.3m
|
CAGR 3-Years
-5%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
N/A
|
|
|
Neuren Pharmaceuticals Ltd
ASX:NEU
|
Total Liabilities
AU$4.4m
|
CAGR 3-Years
38%
|
CAGR 5-Years
42%
|
CAGR 10-Years
6%
|
|
|
C
|
Clarity Pharmaceuticals Ltd
ASX:CU6
|
Total Liabilities
AU$10.9m
|
CAGR 3-Years
13%
|
CAGR 5-Years
63%
|
CAGR 10-Years
N/A
|
|
|
Nyrada Inc
ASX:NYR
|
Total Liabilities
AU$549k
|
CAGR 3-Years
-23%
|
CAGR 5-Years
-6%
|
CAGR 10-Years
N/A
|
|
Emyria Ltd
Glance View
Emyria Ltd. is a healthcare technology and services company. The firm provides care for its patients through its clinics gathering real-world-evidence (RWE) insights in relation to therapies, such as cannabinoid-based medicines and drug development. Its evidence-based drug development program (EMD-003) is focused on mental health and EMD-004 is focused on irritable bowel syndrome (IBS). The Company’s subsidiaries include Emyria Clinical Network Pty Ltd and Openly Care Inc.
See Also
What is Emyria Ltd's Total Liabilities?
Total Liabilities
1.3m
AUD
Based on the financial report for Jun 30, 2025, Emyria Ltd's Total Liabilities amounts to 1.3m AUD.
What is Emyria Ltd's Total Liabilities growth rate?
Total Liabilities CAGR 5Y
0%
Over the last year, the Total Liabilities growth was -56%. The average annual Total Liabilities growth rates for Emyria Ltd have been -12% over the past three years .
